NOMO2 Antibody

What is NOMO2 and what is its biological significance?

NOMO2 (NODAL Modulator 2) is a type I membrane protein approximately 130 kDa in size that functions as a component of the BOS complex. It plays a crucial role in the Nodal signaling pathway during vertebrate development . Structurally, NOMO2 is localized to the endoplasmic reticulum membrane as a single-pass membrane protein .

More specifically, NOMO2 functions as a component of the multi-pass translocon (MPT) complex that mediates insertion of multi-pass membrane proteins into the lipid bilayer of membranes. The MPT complex takes over after the SEC61 complex: following membrane insertion of the first few transmembrane segments of proteins by the SEC61 complex, the MPT complex occludes the lateral gate of the SEC61 complex to promote insertion of subsequent transmembrane regions .

The NOMO2 gene is one of three highly similar genes located in a region of duplication on chromosome 16p13.3. These three genes encode closely related proteins that may share functional characteristics .

What applications are NOMO2 antibodies validated for?

NOMO2 antibodies have been validated for multiple experimental applications, with variations depending on the specific antibody:

When selecting an antibody for a specific application, researchers should verify the validation status for their application of interest rather than assuming cross-application functionality .

What are the standard host organisms and clonality options for NOMO2 antibodies?

Based on available products, NOMO2 antibodies demonstrate the following characteristics:

The predominance of rabbit polyclonal antibodies suggests this format has proven most effective for NOMO2 detection .

How can researchers validate NOMO2 antibody specificity to ensure reliable results?

Antibody validation is critical for ensuring reproducible results. For NOMO2 antibodies, researchers should implement a multi-method validation approach:

• Genetic validation: Use NOMO2 knockout (KO) cell lines as negative controls to verify signal specificity

  • This represents the gold standard for validation as demonstrated by recent Open Science initiatives

• Molecular weight verification: Confirm detection of a specific band at approximately 130 kDa in Western blot

  • In some cases, detection of slight degradation products is normal

• Multi-antibody comparison: Test multiple NOMO2 antibodies targeting different epitopes side-by-side

  • YCharOS (Antibody Characterization through Open Science) has demonstrated this approach successfully with other antibodies

• Cross-application validation: Verify consistent results across multiple applications (WB, IHC, IF)

  • Not all antibodies work equivalently across applications; for example, some antibodies may work well for Western blot but not for IHC

• Peptide competition: Perform blocking experiments with the immunizing peptide where available

  • For example, peptide competition with antibodies raised against specific regions (AA 139-189 or 873-1222)

The recent Open Science platform developed by the Structural Genomics Consortium researchers at McGill University represents an emerging gold standard, where antibodies are systematically characterized using knockout cell lines across multiple applications .

What are the optimal protocols for using NOMO2 antibodies in Western blotting?

Based on validated protocols for NOMO2 antibody applications, the following Western blot methodology is recommended:

• Sample preparation:

  • Prepare cell/tissue lysates under reducing conditions

  • Include protease inhibitors to prevent degradation

• Electrophoresis and transfer:

  • Use PVDF membrane for optimal protein binding

  • Transfer using standard protocols (wet or semi-dry)

• Antibody incubation:

  • Block membrane with appropriate blocking buffer (typically 5% BSA or non-fat milk)

  • Primary antibody dilution: 1:1000-2000 (STJA0006677) or 1 μg/mL (AF3755)

  • Incubate overnight at 4°C for optimal results

  • Secondary antibody: HRP-conjugated anti-rabbit or anti-goat IgG depending on primary antibody host

• Detection:

  • Use appropriate chemiluminescent detection system

  • Expected band: approximately 130 kDa

  • Some antibodies may detect slight degradation products

• Controls:

  • Positive control: LNCaP or HeLa cell lysates have been validated

  • Loading control: Standard housekeeping protein

Western blot conditions should be optimized for each specific NOMO2 antibody, as dilutions and conditions may vary based on the manufacturer's recommendations .

How do epitope differences impact NOMO2 antibody performance?

Different NOMO2 antibodies target distinct epitopes within the protein, significantly affecting their performance characteristics:

Epitope selection considerations:

• Structural accessibility: Epitopes in the extracellular domain are more accessible in native conditions

  • The extracellular domains of NOMO isoforms share 99% amino acid sequence homology

  • Human and mouse NOMO ECDs share 94% amino acid sequence homology

• Conservation: Highly conserved regions provide cross-species reactivity but may reduce isoform specificity

  • Antibodies targeting regions with sequence differences between NOMO1, NOMO2, and NOMO3 may provide isoform specificity

• Application compatibility: Some epitopes may be denatured or masked in certain applications

  • For example, as noted in search result , some antibodies may recognize epitopes revealed during ELISA but not work in other applications

• Post-translational modifications: Consider whether the epitope contains potential modification sites that might affect antibody binding

Researchers should select antibodies targeting epitopes appropriate for their specific experimental questions and applications.

What methods are recommended for troubleshooting weak or non-specific NOMO2 antibody signals?

When encountering suboptimal results with NOMO2 antibodies, systematic troubleshooting is essential:

• For weak or absent signals:

  • Increase antibody concentration (within manufacturer guidelines)

  • Extend incubation time (e.g., overnight at 4°C)

  • Enhance detection sensitivity using amplification systems

  • Verify sample quality and protein expression levels

  • Confirm proper sample preparation (avoiding excessive heat that might denature epitopes)

  • Test alternative antibodies targeting different epitopes

• For non-specific signals:

  • Optimize blocking conditions (try different blocking reagents)

  • Increase washing stringency (more washes, higher detergent concentration)

  • Decrease antibody concentration

  • Pre-adsorb antibody with related proteins if cross-reactivity is suspected

  • Filter antibody solution to remove aggregates

  • Use more specific secondary antibodies

• Application-specific considerations:

  • For IHC/IF: Optimize fixation and antigen retrieval methods

  • For WB: Adjust reducing conditions and detergent concentrations

  • For IP: Modify lysis conditions to preserve protein interactions

• Controls to implement:

  • Positive control: Use samples known to express NOMO2 (e.g., LNCaP or HeLa cell lines)

  • Negative control: Use NOMO2 knockout cells or tissues

  • Secondary-only control: Omit primary antibody to detect non-specific secondary binding

  • Isotype control: Use non-specific IgG from the same species as the primary antibody

Similar to approaches used with SARS-CoV-2 antibodies, optimization across multiple parameters may be required to achieve optimal signal-to-noise ratios .

How can researchers distinguish between NOMO1, NOMO2, and NOMO3 considering their high sequence homology?

Distinguishing between the highly homologous NOMO family members presents a significant challenge:

• Antibody selection strategies:

  • Target regions with sequence divergence between NOMO isoforms

  • Validate antibody specificity using overexpression systems for each isoform

  • Employ knockout/knockdown validation for each specific NOMO protein

• Complementary molecular techniques:

  • Combine antibody detection with qPCR to quantify isoform-specific mRNA levels

  • Use CRISPR-Cas9 to create isoform-specific knockouts as controls

  • Employ mass spectrometry to identify isoform-specific peptides

• Experimental design considerations:

  • Run parallel Western blots with isoform-specific positive controls

  • Include competition assays with recombinant proteins

  • Perform titration experiments to identify concentration-dependent specificity profiles

• Analytical approaches:

  • Use computational algorithms to deconvolute signals from multiple isoforms

  • Implement statistical methods to account for cross-reactivity

Given that the extracellular domains of NOMO isoforms share 99% amino acid sequence homology , researchers must carefully evaluate antibody specificity data and consider whether their experimental question requires isoform-specific detection or can accommodate pan-NOMO detection.

What is the current understanding of NOMO2's role in the Nodal signaling pathway and embryonic development?

NOMO2 functions as part of a protein complex that regulates Nodal signaling during embryonic development:

• Molecular interactions:

  • NOMO2 is a binding partner of Nicalin, a nicastin-related protein

  • The Nicalin/NOMO complex localizes to the endoplasmic reticulum

  • This complex functions as an antagonist for Nodal and Activin signaling

• Developmental significance:

  • Nodal signaling is critical for mesoderm formation and axial patterning during embryonic development

  • NOMO2's antagonistic role helps regulate the spatial and temporal aspects of this signaling

  • Proper balance between activators and inhibitors of Nodal signaling is essential for normal development

• Emerging cellular functions:

  • Recent research has identified NOMO2 as a component of the multi-pass translocon (MPT) complex

  • This complex mediates insertion of multi-pass membrane proteins into lipid bilayers

  • The MPT complex takes over after the SEC61 complex in membrane protein insertion

• Experimental approaches to study NOMO2's developmental roles:

  • Knockout/knockdown studies in model organisms

  • Co-immunoprecipitation to identify binding partners

  • Reporter gene assays to study effects on Nodal signaling

  • Immunohistochemistry to track expression patterns during development

Further research using validated NOMO2 antibodies will continue to elucidate this protein's specific roles in developmental processes and membrane protein insertion.

How do storage and handling conditions affect NOMO2 antibody performance?

Proper storage and handling are critical for maintaining antibody performance:

Critical handling considerations:

• Temperature management:

  • Use manual defrost freezers to avoid temperature fluctuations

  • Avoid repeated freeze-thaw cycles which can cause protein denaturation and aggregation

  • Aliquot antibodies upon receipt to minimize freeze-thaw cycles

• Buffer considerations:

  • Most NOMO2 antibodies are supplied in buffers containing:

    • PBS with 0.1% sodium azide

    • 50% glycerol

    • pH 7.3

  • Note safety precautions: Sodium azide is a poisonous and hazardous substance requiring trained handling

• Working dilution preparation:

  • Prepare fresh working dilutions on the day of use

  • Return stock solutions to appropriate storage conditions immediately

  • Centrifuge briefly before opening to collect solution at the bottom of the vial

• Contamination prevention:

  • Use sterile technique when handling antibodies

  • Avoid introducing microorganisms that could degrade the antibody

  • Consider adding preservatives for diluted working solutions

Adhering to these storage and handling guidelines will help ensure consistent antibody performance across experiments and maximize the usable lifespan of valuable research reagents.

How can new antibody validation technologies improve NOMO2 research reproducibility?

Recent advances in antibody validation technologies offer significant opportunities to enhance NOMO2 research reproducibility:

• Open Science validation platforms:

  • The YCharOS (Antibody Characterization through Open Science) initiative exemplifies standardized approaches to antibody validation

  • This platform evaluates antibodies using knockout cell lines across multiple applications

  • Industry collaboration has enabled side-by-side testing of commercially available antibodies

• Multi-modal validation strategies:

  • Combining genetic, biochemical, and immunological validation approaches

  • Integration of mass spectrometry-based validation with traditional antibody-based detection

  • Using computational prediction of antibody specificity based on epitope mapping

• Deep learning approaches:

  • Machine learning algorithms to predict antibody specificity

  • AI-driven analysis of antibody binding profiles across proteomes

  • The Virtual Lab concept (similar to that used for nanobody design) could be applied to antibody validation

• Impact on research reproducibility:

  • Standardized validation reduces the estimated $1 billion of research funding wasted annually on non-specific antibodies

  • Enhanced reproducibility through clear reporting of validation methods

  • Community-driven validation databases to share experiences with specific antibodies

Implementation of these emerging technologies for NOMO2 antibody validation would significantly enhance research reproducibility and accelerate scientific discovery in this field.

What methodological approaches are recommended for studying NOMO2 interactions with binding partners?

Investigating NOMO2's protein interactions requires specialized methodological approaches:

• Co-immunoprecipitation (Co-IP) strategies:

  • Use NOMO2 antibodies verified for immunoprecipitation

  • Optimize lysis conditions to preserve protein-protein interactions

  • Consider crosslinking approaches for transient interactions

  • Validate interactions with reciprocal Co-IP using antibodies against binding partners

  • Controls should include IgG isotype controls and NOMO2 knockout cells

• Proximity-based interaction methods:

  • BioID or TurboID for proximity labeling

  • FRET/BRET for real-time interaction monitoring

  • Proximity Ligation Assay (PLA) for visualizing interactions in situ

  • Split-protein complementation assays to validate direct interactions

• Structural biology approaches:

  • Apply computational prediction tools like AlphaFold-Multimer to model NOMO2 complexes

  • Use similar approaches to those described for SARS-CoV-2 nanobody design

  • Combine with experimental validation using antibodies to verify predicted interactions

• Systems biology methods:

  • Proteomic profiling of NOMO2 interactome

  • Network analysis to identify functional interaction clusters

  • Perturbation studies to assess interaction dynamics

• Visualization techniques:

  • Multi-color immunofluorescence to co-localize NOMO2 with potential interactors

  • Super-resolution microscopy to visualize nanoscale proximity

  • Live-cell imaging to track dynamic interactions

These methodological approaches can reveal NOMO2's protein interaction network and elucidate its role in cellular signaling and membrane protein insertion.

How can researchers integrate NOMO2 antibody data with other research techniques for comprehensive functional analysis?

A multi-omics approach integrating antibody-based detection with complementary techniques provides the most comprehensive functional analysis of NOMO2:

• Integration with genomic techniques:

  • Combine ChIP-seq (using NOMO2-interacting transcription factors) with antibody-based protein detection

  • Correlate NOMO2 protein levels with gene expression profiles

  • Use CRISPR screens to identify genetic interactions with NOMO2

• Integration with proteomic approaches:

  • Combine antibody-based detection with mass spectrometry for validation

  • Assess post-translational modifications of NOMO2 using modification-specific antibodies

  • Map protein interaction networks using both antibody-based and label-free methods

• Integration with imaging technologies:

  • Correlate antibody-based localization with live-cell reporters

  • Combine with electron microscopy for ultrastructural localization

  • Implement tissue clearing techniques with antibody staining for 3D visualization

• Integration with functional assays:

  • Combine antibody detection with reporter gene assays for Nodal signaling

  • Correlate protein expression with membrane protein insertion efficiency

  • Use antibody-based protein quantification alongside cell-based functional assays

• Data integration frameworks:

  • Develop computational pipelines to integrate antibody-based quantification with transcriptomic and proteomic data

  • Apply machine learning approaches to identify patterns across multi-omics datasets

  • Implement systems biology modeling informed by antibody-validated protein levels

This integrated approach, similar to the interdisciplinary methods being applied in SARS-CoV-2 research , provides a more complete understanding of NOMO2 biology than any single technique alone.